Taisho Pharmaceutical Holdings Co., Ltd.

OTCPK:TAIP.Y Rapporto sulle azioni

Cap. di mercato: US$4.6b

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Taisho Pharmaceutical Holdings Performance dei guadagni passati

Il passato criteri di controllo 0/6

Taisho Pharmaceutical Holdings's earnings have been declining at an average annual rate of -25.1%, while the Pharmaceuticals industry saw earnings growing at 0.03% annually. Revenues have been growing at an average rate of 2.9% per year. Taisho Pharmaceutical Holdings's return on equity is 1.3%, and it has net margins of 2.6%.

Informazioni chiave

-25.1%

Tasso di crescita degli utili

-25.9%

Tasso di crescita dell'EPS

Pharmaceuticals Crescita del settore6.0%
Tasso di crescita dei ricavi2.9%
Rendimento del capitale proprio1.3%
Margine netto2.6%
Ultimo aggiornamento sui guadagni31 Dec 2023

Aggiornamenti sulle prestazioni recenti

Recent updates

Ripartizione dei ricavi e delle spese

Come Taisho Pharmaceutical Holdings guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.

Storia dei guadagni e delle entrate

OTCPK:TAIP.Y Ricavi, spese e utili (JPY Millions )
DataRicaviGuadagniSpese G+ASpese di R&S
31 Dec 23320,3858,421143,52620,727
30 Sep 23319,96015,570138,81220,727
30 Jun 23313,11417,609136,76020,727
31 Mar 23301,38118,997134,10420,727
31 Dec 22295,82125,047131,88619,366
30 Sep 22282,56021,091131,63819,366
30 Jun 22273,38817,694133,20919,366
31 Mar 22268,20313,122133,72219,366
31 Dec 21267,7318,055135,03620,251
30 Sep 21266,2414,930134,70120,251
30 Jun 21270,8418,431134,99520,251
31 Mar 21281,98013,316135,77020,251
31 Dec 20291,48916,837135,08222,876
30 Sep 20302,21916,846140,06622,876
30 Jun 20303,29015,589140,90422,876
31 Mar 20288,52720,531136,04722,876
31 Dec 19272,99315,124132,21720,801
30 Sep 19264,26821,138123,10020,801
30 Jun 19260,06345,910118,74220,801
31 Mar 19261,55148,593118,15020,801
31 Dec 18264,19056,614115,41721,150
30 Sep 18270,95362,097118,78721,150
30 Jun 18273,30839,834119,88821,150
31 Mar 18280,09231,679124,85721,150
31 Dec 17279,14031,574125,33921,260
30 Sep 17277,39627,298125,70221,260
30 Jun 17278,87427,370127,05621,260
31 Mar 17279,77328,781125,00021,260
31 Dec 16281,58827,438124,30621,768
30 Sep 16285,15824,691124,66521,768
30 Jun 16290,35424,732124,24021,768
31 Mar 16290,13522,473126,16721,768
31 Dec 15293,71723,594126,16621,554
30 Sep 15294,67723,217127,42221,554
30 Jun 15291,33922,556148,8090
31 Mar 15290,49824,529124,72021,554
31 Dec 14289,77724,493126,87621,874
30 Sep 14293,19928,769124,44321,874
30 Jun 14296,15031,940122,24621,874
31 Mar 14295,95832,693121,13521,875
31 Dec 13292,83832,311117,99823,331
30 Sep 13289,77930,170118,79723,331

Guadagni di qualità: TAIP.Y has a large one-off loss of ¥7.9B impacting its last 12 months of financial results to 31st December, 2023.

Margine di profitto in crescita: TAIP.Y's current net profit margins (2.6%) are lower than last year (8.5%).

Flusso di cassa libero e analisi degli utili

Analisi della crescita degli utili nel passato

Andamento degli utili: TAIP.Y's earnings have declined by 25.1% per year over the past 5 years.

Accelerare la crescita: TAIP.Y's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Guadagni vs Settore: TAIP.Y had negative earnings growth (-66.4%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (15.5%).

Rendimento del capitale proprio

ROE elevato: TAIP.Y's Return on Equity (1.3%) is considered low.

Rendimento delle attività

Rendimento del capitale investito

Scoprire le aziende con forti performance passate

7D

1Y

7D

1Y

7D

1Y